In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
CMOs showed an increasing reluctance to take on debt in 2022
Approval to dramatically change CAR-T therapies landscape
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Pfizer is likely to show GSK significant competition
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Subscribe To Our Newsletter & Stay Updated
